TRPV1 ligands with hyperthermic, hypothermic and no temperature effects in rats

Arthur Gomtsyan*, Heath A McDonald*, Robert G Schmidt, Jerome F Daanen, Eric A Voight, Jason A Segreti, Pamela S Puttfarcken, Regina M Reilly, Michael E Kort, Michael J Dart, and Philip R Kym

Research & Development; AbbVie Inc.; Chicago, IL USA

Keywords: chromanyl ureas, hyperthermia, hypothermia, TRPV1, TRPV1 antagonists, TRPV1 agonists, 5'-iodo-RTX, thermoregulation

Abbreviations: TRPV1, transient receptor potential vanilloid 1; FLIPR, fluorometric imaging plate reader; OA, osteoarthritis; Compound 1, (R)-1-(2,2-dimethyl-7-(trifluoromethyl)chroman-4-yl)-3-(3,6-dimethylisoquinolin-5-yl)urea; Compound 2, (R)-1-(2,2-dimethyl-7-(trifluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea; Compound 3, (R)-1-(2,2-dimethyl-8-(trifluoromethoxy)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea; 5'-I-RTX, 5'-iodo-resiniferatoxin.

Introduction

Transient receptor potential vanilloid 1 (TRPV1) is a multifunctional ion channel playing important roles in a numerous biological processes including the regulation of body temperature. Within distinct and tight chemical space of chromanyl ureas TRPV1 ligands were identified that exhibit distinctive pharmacology and a spectrum of thermoregulatory effects ranging from hypothermia to hyperthermia. The ability to manipulate these effects by subtle structural modifications of chromanyl ureas may serve as a productive approach in TRPV1 drug discovery programs addressing either side effect or desired target profiles of the compounds. Because chromanyl ureas in the TRPV1 context are generally antagonists, we verified observed partial agonist effects of a subset of compounds within that chemotype by comparing the in vitro profile of Compound 3 with known partial agonist 5'-I-RTX.

Materials and Methods

5'-I-RTX was purchased from Sigma Aldrich. Other reagents were sourced as described. Functional studies were conducted.
on a fluorometric imaging plate reader (FLIPR_TETRA) which monitored effects of capsaicin or mild acid on Ca2+ uptake into recombinant HEK293 cells expressing rat or human TRPV1 as described previously. Antagonism of heat activation was measured at 48°C by using a custom made device (GNF Systems, San Diego, CA) for the control of temperature. Telemeters were inserted into male Sprague-Dawley rats and temperature was monitored as detailed elsewhere. Pharmacokinetic parameters were monitored by procedures as described.

Results

Compound 1, Compound 2, Compound 3, and 5'-I-RTX exhibit different pharmacological profiles against polymodal activation of recombinant rat and human TRPV1

The ability of Compound 1, Compound 2, and Compound 3 to inhibit TRPV1 activation was investigated using recombinant HEK293 cells expressing rat or human TRPV1. All three chromans as well as 5'-I-RTX were competitive with 50 nM capsaicin at both rat and human TRPV1 and elicited potent antagonism (Table 1). These compounds were also evaluated for activity on pH 5-stimulated rat and human TRPV1. Acidic responses at rat TRPV1 were blocked fully by Compound 1, partially by Compound 2, and not by Compound 3 (Fig. 1) or <11.25 μM 5'-I-RTX (Fig. 2). Both Compound 3 and 5'-I-RTX elicited partial agonism upon addition to recombinant rat TRPV1 (Fig. 3) while Compound 1 and Compound 2 did not.

All three chromanyl urea compounds potently blocked heat activation of human TRPV1 with IC50 values of 20 nM, 5 nM and 17 nM for Compounds 1, 2, and 3, respectively. Additionally, these compounds were selective against human “cold” receptors TRPA1 and TRPM8 exhibiting no activity up to 100 μM at TRPA1 and IC50 values of >100 μM, 30 μM, and 25 μM at TRPM8 for Compounds 1, 2, and 3, respectively.

Pharmacological profiles of Compound 1 and Compound 2 at human TRPV1 were similar to their profiles at rat TRPV1; the former fully blocked acid activation, while <11.25 μM of the latter partially blocked the channel (Fig. 4). However, in vitro data for 2 other compounds, Compound 3 and 5'-I-RTX, were distinctly different at human versus rat TRPV1. Both compounds behaved as partial blockers upon pH 5 activation of human – but not rat – TRPV1. Moreover, Compound 3 and 5'-I-RTX did not activate human TRPV1 when applied to recombinant HEK293 cells at pH 5.

Table 1. Potencies of Compound 1, Compound 2, Compound 3, and 5'-I-RTX at rat and human TRPV1 Potencies were determined by using Ca2+ flux assays performed on the FLIPR_TETRA. All compounds completely blocked capsaicin-evoked responses at rat and human TRPV1. The concentration of compounds used to determine the percentage of inhibition against acid stimulation was 11.25 μM. Results are shown as mean values and SD for at least 2–4 determinations. ND represents data not determined due to insufficient block of pH 5 activation.

| Compound   | Capsaicin IC50 (nM) | Acid IC50 (nM) | Acid % inhibition | Capsaicin IC50 (nM) | Acid IC50 (nM) | Acid % inhibition |
|------------|---------------------|----------------|------------------|---------------------|----------------|------------------|
| Compound 1 | 546 +/- 26.3        | 72.7 +/- 8.0   | 99.7 +/- 0.1     | 144.0 +/- 9.4       | 107.0 +/- 18.3 | 95.4 +/- 1.8     |
| Compound 2 | 20.9 +/- 3.1        | ND             | 20.1 +/- 8.5     | 17.8 +/- 16.3       | 20.1 +/- 7.3  | 76.2 +/- 6.6     |
| Compound 3 | 429.0 +/- 162.0     | ND             | -5.1 +/- 9.2     | 65.7 +/- 10.6       | ND             | 35.4 +/- 2.1     |
| 5'-I-RTX   | 200.0 +/- 90.3      | ND             | -3.0 +/- 0.55    | 274.0 +/- 28.3      | 114.0 +/- 50.7| 64.4 +/- 11.1    |

Discussion

First generation TRPV1 antagonists increase body temperature in both preclinical species and humans. Efforts in our group to develop different series of TRPV1 antagonists led to discovery of the chromanyl urea chemotype. Potent compounds within this narrow structural class exhibit significantly diverse pharmacological responses at TRPV1 and thermoregulatory effects. Minor structural manipulations generate compounds that elicit effects in rats ranging from hypothermia to hyperthermia. Thus, Compound 1 increases body temperature 1.4°C at a relatively low plasma concentration of 0.7 μg/mL (Fig. 1). Removal of the methyl group in the isoquinoline fragment of Compound 1 generated Compound 2 that does not affect temperature in rats at concentrations 2-fold higher than efficacious plasma levels in the OA pain model (Fig. 1). On the other hand,
replacing the trifluoromethyl group in Compound 2 with a trifluoromethoxy group and moving it from the 7-position to the adjacent 8-position of the chroman fragment results in Compound 3 which elicits hypothermic effects of about \(-2^\circ\text{C}\) (Fig. 1). Temperature-elevating and temperature-neutral effects of TRPV1 antagonists correlate with the pharmacological profile of TRPV1 antagonists. Compounds that inhibit all modes of channel activation (represented, e.g., by capsaicin, heat, and acid and exemplified by Compound 1) would be expected to increase body temperature, while compounds that potently block capsaicin – but not other modes of TRPV1 activation – (e.g., Compound 2) would not be expected to affect core body temperature in rats. While these observations proved largely consistent over the course of an aggressive campaign to identify temperature-neutral TRPV1 antagonists, select compounds with distinctly different properties have been identified. For example, it was initially difficult to explain hypothermia evoked by Compound 3 (Fig. 1). According to the generally accepted in vitro/in vivo relationship for TRPV1 ligands, this compound – potent against capsaicin and weak against acid activation – would be expected to be

**Figure 1.** Effects of TRPV1 ligands on acid-induced Ca\(^{2+}\) flux into recombinant HEK293 cells expressing rat TRPV1 and on rat core body temperature. Representative Ca\(^{2+}\) flux responses as monitored in FLIPR traces are shown for Compound 1, Compound 2, and Compound 3 (11.25 \(\mu\text{M}\)) to demonstrate their effects on acid activation of rat TRPV1. The change in rat core body temperature represents mean and SEM for at least 5 determinations. (A) Compound 1 is a full acid blocker of rat TRPV1 and elicits hyperthermia in rats. (B) Compound 2 is a partial acid blocker of rat TRPV1 and does not affect core body temperature in rats. (C) Compound 3 is a partial agonist that does not block acid activation of rat TRPV1 and evokes hypothermia in rats.

**Figure 2.** Effects of 5'-I-RTX on acid-induced Ca\(^{2+}\) flux into recombinant HEK293 cells expressing rat TRPV1. The pharmacological profile of 11.25 \(\mu\text{M}\) 5'-I-RTX against acid (pH 5.0) activation is illustrated in a representative FLIPR trace to demonstrate that 5'-I-RTX is a partial agonist and an acid non-blocker of rat TRPV1.
temperature-neutral in preclinical models. Yet Compound 3 proves hypothermic in rats, an effect typically associated with TRPV1 small molecule agonists such as capsaicin. Close inspection of the FLIPR curves of Compound 3 reveals subtle activation of the channel upon application of the compound directly to HEK293 cells expressing recombinant TRPV1. This observation suggests that Compound 3 evokes partial agonism. The signal is minimal but is consistently reproducible among select hypothermic TRPV1 ligands in the chromanyl urea series. In order to probe further into this observation the behavior of 5'-I-RTX, a well documented partial agonist of TRPV1, was examined in the identical FLIPR setting. This analog of the ultrapotent TRPV1 agonist RTX was originally classified as a TRPV1 antagonist based on in vitro data generated with recombinant and native TRPV1 cells. However, profound hypothermic effects of this compound in mice were inconsistent with TRPV1 antagonism predicted from its in vitro behavior. This paradoxical link between TRPV1 antagonism and hypothermia triggered extensive in vitro functional studies which demonstrated that 5'-I-RTX is a partial agonist of TRPV1. Comparison of FLIPR profiles of 5'-I-RTX and Compound 3 indicates that both compounds elicit Ca\textsuperscript{2+} influx into recombinant rat TRPV1 cells in a qualitatively similar manner, supporting the conclusion that Compound 3 is a partial agonist of the channel (Fig. 3). Interestingly, compounds with distinct pharmacological profiles (Compound 2, Compound 3, and 5'-I-RTX) evoke different responses in human versus rat TRPV1 (Fig. 4). Compound 2, Compound 3, and 5'-I-RTX more potently inhibit acid-evoked responses at human TRPV1. There is no indication of partial agonism for latter 2 compounds. Such interspecies differences in the pharmacology of TRPV1 ligands serve as a caution in projecting thermoregulatory effects from in vitro pharmacology and preclinical models to the clinical setting.

Discovery of compounds with a wide range of pharmacological profiles within one well defined structural scaffold such as chromanyl ureas represents a useful finding for TRPV1 drug discovery and may provide an economical and effective way of identifying full antagonists, modality-specific antagonists, or partial agonists from a common structural core with favorable drug-like properties. However, despite recent advances, discovering a TRPV1 ligand with desired pharmacology remains more of an empirical than rational exercise. Nevertheless, recent advances in structural analysis of TRPV1 may provide meaningful support for more predictable structure-based drug design. In 2013 the structure of rat TRPV1 was determined by single particle electron cryo-microscopy revealing architecture of the channel. Further investigation of rat TRPV1-ligand complex by electron cryo-microscopy and molecular docking experiments with
a human TRPV1 homology model’ve provide useful information on restriction points of the protein as selectivity filter and lower gate. These data along with earlier mutagenesis studies’ve are starting to provide insight into TRPV1 ligand binding pockets and associated conformational changes upon binding of agonists and antagonists to TRPV1.

Conclusions

In summary, slight variation of the nature or position of substituents in a structurally distinct chromanyl urea scaffold exerts significant impact on the pharmacological behavior of TRPV1 ligands and, as a consequence, produces a variety of thermoregulatory effects in rats ranging from hyperthermia to hypothermia. In vitro pharmacological profiles and thermoregulatory effects of representatives from 3 subsets of chromanyl urea TRPV1 ligands that are closely related are described. Compound 1 inhibits both capsaicin- and acid-evoked responses in rat TRPV1 and evokes hyperthermic effects in rats. Compound 2 fully blocks capsaicin activation, only partially blocks acid response, and does not evoke significant temperature effects in rats. Compound 3 has been shown to be a partial agonist and produces hypothermic effects in rats. The latter shows no agonist effects at recombinant human TRPV1. Similarly 5’-I-RTX behaves as partial agonist at recombinant rat – but not human – TRPV1. Ability to generate and characterize TRPV1 ligands with different pharmacological and thermoregulatory profiles within the same structural class of compounds may accelerate the discovery of still more effective modulators of the TRPV1 channel. Although Compounds 1–3 display favorable selectivity profiles against other thermosensory receptors, TRPA1 and TRPM8, a possibility of non-TRPV1-mediated thermal effects or lack thereof cannot be fully excluded.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Gees M, Owsianik G, Nilus B, Voets T. TRP channels. Comp Physiol 2012; 2:563-608; PMID:23728980
2. Vrien J, Nilus B, Voets T. Peripheral thermo-sensation in mammals. Nature Rev Neurosci 2014; 15:573-89; PMID:25053448; http://dx.doi.org/10.1038/nrn3578
3. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateWay to the pain pathway. Annu Rev Neurosci 2001; 24:487-517; PMID:11283319; http://dx.doi.org/10.1146/annurev.neuro.24.1.487
4. Szallasi A, Cottright DN, Blum CA, Eid SR. The vanill-oid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6:357-72; PMID:17464295; http://dx.doi.org/10.1038/nrd2280
5. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Cohen G, Rothman EK, Basbaum AI, Chao MV, Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288:306-13; PMID:10764768; http://dx.doi.org/10.1126/science.288.5464.306
6. Davis JB, Gray J, Gunthorpe MJ, Hancher JP, Davey PT, Overend P, Harris MH, Latchman J, Clapham C, Arkinon K, et al. Vaniloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 406:734-7; PMID:10821274; http://dx.doi.org/10.1038/35012076
7. Chuang HH, Prescott ED, Kong H, Shields J, Jordt SE, Basbaum AI, Chau MV, Julius D. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001; 411:957-62; PMID:11418861; http://dx.doi.org/10.1038/35082088
8. Patapoutian A, Tare S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov 2009; 8:55-69; PMID:19116627; http://dx.doi.org/10.1038/nrd2757
9. De Petrocellis L, Morrilllo AS. Modulation of the TRPV1 channel. Current clinical trials and recent patents with focus on neurological conditions. Recent Pat CNS Drug Discov 2013; 8: 180-204; PMID:24230132
10. Trevisani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain Journul 2013; 6:108-18; http://dx.doi.org/10.2174/1876386301306010108
11. Gomtsyan A, Brederoo JD. Clinical and Preclinical Experience with TRPV1 Antagonists as Potential Analgesic Agents. In: Stalhali A, ed. TRP Channels as Therapeutic Targets: from Basic Science to Clinical Use. Academic Press: 2015:129-45.
12. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovskaya AA. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermy. J Neurosci 2010; 30:1435-40; PMID:20107070; http://dx.doi.org/10.1523/JNEUROSCI.5150-09.2010
13. Reilly RM, McDonald HA, Puttarfacken PS, Joshi SK, Lewis L, Pai M. Pharmacology of modality-specific transient receptor potential vanilloid-1 agonists that do not alter body temperature. J Pharmacol Exp Ther 2012; 342:416-28; PMID:22570364; http://dx.doi.org/10.1124/jpet.111.190310
14. Voight EA, Gomtsyan A, Daanen JF, Perner RJ, Schmidt MG, Bayburt EK. US Patent Application US 2013/0345255 (2013).
15. Liao M, Cao E, Julius D, Cheng Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature 2013; 504:107-12; PMID:24305160; http://dx.doi.org/10.1038/nature12822
16. Feng Z, Pearce LV, Xu X, Yang X, Yang P, Blumberg PM, Xiang-Qin Xie X-Q. Structural insight into tetra-meric bTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations. J Chem Inf Model 2015; 55:572-88; PMID:25642729; http://dx.doi.org/10.1523/JNEUROSCI.5150-09.2010
17. Shimizu I, Iida T, Horinouchi N, Caterina MJ. 5-Iodore-siniferatoxin evokes hyperthermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther 2005; 303:105-12; PMID:15947039
18. Liao M, Cao E, Julius D, Cheng Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature 2013; 504:107-12; PMID:24305160; http://dx.doi.org/10.1038/nature12822
19. Cao E, Liao M, Cheng Y, Julius D. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature 2013; 504:113-18; PMID:24305161; http://dx.doi.org/10.1038/nature12823
20. Feng Z, Pearce LV, Xu X, Yang X, Yang P, Blumberg PM, Xiang-Qin Xie X-Q. Structural insight into tetra-meric bTRPV1 from homology modeling, molecular docking, molecular dynamics simulation, virtual screening, and bioassay validations. J Chem Inf Model 2015; 55:572-88; PMID:25642729; http://dx.doi.org/10.1038/jb.2010.056
21. Chow MX, Mzi T, Gao YD, Kohler M, Middleton RE. Resiniferatoxin binds to the capsaicin receptor (TRPV1) near the extracellular side of the S4 transmembrane domain. Biochemistry 2004; 43:25011-22; PMID:14992587; http://dx.doi.org/10.1021/bi035981h
22. Gavva NR, Klondyk L, Qu Y, Shi L, Tamir R, Edenson S, Zhang Tji, Voswanathan VN, Toth A, Pearce LV, et al. Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 2004; 279: 20283-95; PMID:14995688; http://dx.doi.org/10.1074/jbc.M312577200
23. Jordt SE, Julius D. Molecular basis for species-specific sensitivity to “hot” chili peppers. Cell 2002; 108:421-30; PMID:11853075; http://dx.doi.org/10.1016/S0092-8674(02)00607-2
24. Phillips E, Reeve A, Bevan S, McIntyre P. Identification of species-specific determinants of the action of the antagonist capsazepine and the agonist PPAHV on TRPV1. J Biol Chem 2004; 279:17165-72; PMID:14969039; http://dx.doi.org/10.1074/jbc.M313328200